HR 3950

Responsibility in Drug Advertising Act of 2005

Congress: 109 (2005–2007, Ended)
Chamber: House
Policy Area: Health
Introduced: Sep 29, 2005
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Oct 17, 2005)
Official Text: https://www.congress.gov/bill/109th-congress/house-bill/3950

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]
Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Emerson, Jo Ann [R-MO-8]	R · MO		Sep 29, 2005
Rep. Conyers, John, Jr. [D-MI-14]	D · MI		Nov 1, 2005
Rep. Emanuel, Rahm [D-IL-5]	D · IL		Nov 1, 2005
Rep. McCollum, Betty [D-MN-4]	D · MN		Nov 1, 2005
Rep. Miller, George [D-CA-7]	D · CA		Nov 1, 2005
Rep. Stark, Fortney Pete [D-CA-13]	D · CA		Nov 1, 2005
Rep. Wasserman Schultz, Debbie [D-FL-20]	D · FL		Nov 1, 2005
Rep. McDermott, Jim [D-WA-7]	D · WA		Nov 3, 2005
Rep. Doggett, Lloyd [D-TX-25]	D · TX		Jun 15, 2006
Rep. Sanders, Bernard [I-VT-At Large]	I · VT		Jun 28, 2006

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 17, 2005

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 29, 2005)

Responsibility in Drug Advertising Act of 2005 - Amends the Federal Food, Drug, and Cosmetic Act to prohibit any person from conducting direct-to-consumer advertising of a prescription drug for three years after approval of such drug.

Allows the Secretary of Health and Human Services to: (1) waive such prohibition if such advertising will have an affirmative value to public health; or (2) extend such prohibition for subsequent years if the drug has significant adverse effects.

Provides for civil penalties for violations relating to prescription drug advertisement or promotion. Allows the Secretary to require distribution of corrective information to notify the public and medical community of the violation.

Allows the Secretary to: (1) require information to be included in the labeling of a drug if such information is necessary to ensure the safe and effective use of the drug; and (2) require the manufacturer of a drug to notify the public and the medical community of the labeling change. Deems a drug to be misbranded if such labeling or notification requirements are not met.

Requires the Secretary to conduct an education campaign to increase public awareness of risks that may outweigh the benefits of using a particular drug, whether such risks are known at the time of the approval of the drug or become known later.

Actions Timeline

- **Oct 17, 2005:** Referred to the Subcommittee on Health.
- **Sep 29, 2005:** Introduced in House
- **Sep 29, 2005:** Introduced in House
- **Sep 29, 2005:** Referred to the House Committee on Energy and Commerce.